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increased projected annual cost of $998 per overweight person
with CMR factors. CONCLUSION: CMR factors are more
prevalent and lead to signiﬁcantly greater costs in an overweight
population. Weight loss interventions of overweight patients may
potentially decrease CMR factors and their associated costs.
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OBJECTIVE: To determine the extent to which diabetes among
obese and morbidly obese subjects affects health care costs, and
to determine whether obesity and morbid obesity remain pre-
dictors of health care costs after controlling for diabetes.
METHODS: Data from the Medical Expenditure Panel Survey
(MEPS) for 2000–2004 are examined. Multivariate models are
estimated to predict the probability of incurring any health care
costs and health care costs incurred. These models include
obesity and morbid obesity, diabetes, age, education, occupation
category and race. Models are estimated separately by gender.
Estimates of out-of-pocket, insurer, and total costs are obtained.
Both per capita and national aggregate cost estimates are
obtained. RESULTS: Both out-of-pocket costs rise dramatically
among obese and morbidly obese subjects who are diabetic.
Relative to healthy weight individuals, out-of-pocket costs for
obese diabetics increase by $1002 per annum for females and
$1051 for males. The cost increases are even greater among
morbidly obese diabetics—$1551 for females and $1555 for
males. Insurer costs increase for obese diabetics are $3897 for
females and $3651 for males. Among morbidly obese diabetics,
these cost increases total $7302 for females and $8008 for males.
The aggregate out-of-pocket costs of obesity total $9.7 billion, of
which $8.2 billion, or 85%, are incurred by obese or morbidly
obese diabetics. Aggregate costs to insurers total $56.3 billion, of
which $32.2 billion, or 57%, are due to obese or morbidly obese
diabetics. CONCLUSION: Obese and morbidly obese diabetics
account for a disproportionate share of health care costs among
the obese population as a whole. Efforts to prevent diabetes in
this population and to reduce diabetes among obese and mor-
bidly obese individuals will lead to very substantial cost savings
to insurers and consumers.
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OBJECTIVE: Lenalidomide in combination with high-dose dex-
amethasone (Len + Dex), yields improved time to progression
(TTP) and survival compared to high-dose dexamethasone alone
(Dex). This study aimed to estimate long-term health and cost
consequences of Len + Dex versus Dex in Scottish patients with
multiple myeloma (MM) who have received one prior therapy.
METHODS: A discrete event simulation of a patient’s course
following initiation of Len + Dex or Dex was developed. The
model uses patient’s response (complete, partial, stable disease or
progressive disease) and estimates corresponding TTP and sub-
sequent survival based on Weibull functions derived from pooled
data from two Phase III randomized clinical trials and long-term
outcomes of UK Medical Research Council MM trials. Adverse
events and disease management costs are included. Utility by
response level was obtained from literature. Patients remain on
treatment until relapse. Disease management costs reﬂect clinical
practice in Scotland. Costs and health outcomes are discounted
at 3.5% per annum. In the base case, events and costs are
considered over two years reﬂecting trial follow-up (survival is
modeled until death). 1000 patients are simulated per analysis.
Univariate sensitivity analyses are performed around key model
parameters. RESULTS: The modeled median TTP is conservative
with Len + Dex at 13.5 months compared with 4.7 months with
Dex. This translates to QALY gains: 3.19 vs 1.39. Totals costs
with Len + Dex were £56,155 compared to £3819 with Dex,
leading to an incremental cost-effectiveness ratio of £28,980 per
QALY. Sensitivity analyses showed that outcomes remain consis-
tent through broad changes in key parameters. CONCLUSION:
Lenalidomide delivers signiﬁcant improvements in quality-
adjusted survival in a life-limiting orphan disease and yields an
estimated incremental cost per QALY which falls within a cost-
effective range.
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OBJECTIVE: To evaluate the cost-effectiveness of Erythropoie-
sis Stimulating Agent (ESA) therapy by hemoglobin (Hb)
targets (Hb < 10, 10–11, 11–12, 12–13, and >13 g/dL) in
Chronic Kidney Disease (CKD) considering the complication of
cardiovascular diseases (CVD). METHODS: Two lifetime deci-
sion analyses models for hemodialysis and pre-dialysis patients
using backward induction method were developed using
parameter values from published literatures and 2006 United
States Renal Data System. Direct costs (anemia medication
(erythopoietin or darbepoetin), hemodialysis and CVD treat-
ment) and indirect costs (patient and caregiver time cost) were
measured in 2006 US Dollars. Effectiveness was measured as
quality-adjusted life years (QALYs). All costs and QALYs were
discounted at 3% and cost-effectiveness was measured as incre-
mental cost per QALYs gained (ICER). Uncertainty was evalu-
ated using one way sensitivity analyses and threshold analyses.
RESULTS: For hemodialysis patients who initiated treatment at
age 45, higher hemoglobin targets yielded favorable ICERs
($20,050, $90,387, $67,199 and $11,216 for Hb 10–11 com-
pared to Hb < 10, Hb 11–12 compared to Hb 10–11, Hb
12–13 compared to Hb 11–12, and Hb > 13 compared to Hb
12–13, respectively). For pre-dialysis patients, Hb 11–12 and
Hb 12–13 were dominant strategies compared to Hb 10–11
and Hb 11–12, and ICER for Hb 12–13 compared to Hb > 13
was $2404. The results were more favorable for older patients
and darbepoetin treatment. Results were robust to sensitivity
analyses in pre-dialysis model, but sensitive to the CVD prob-
abilities and erythropoietin costs in hemodialysis model. CON-
CLUSION: Anemia treatment with ESA therapy was cost
effective even in Hb > 13 for hemodialysis patients using a
threshold of ICER $120,000 compared to Hb 12–13. For pre-
dialysis patients, treatment to Hb 12–13 was the most cost
effective. These results showed that higher treatment targets
compared to current national guidelines (maintaining Hb
11–12, not exceeding 13) are associated with favorable cost-
effectiveness ratios. This is consistent with Medicare’s revised
payment policies for ESA treatment.
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